LSE:AZNPharmaceuticals
AstraZeneca’s China Expansion And CSPC Alliance Reframe Obesity Investment Case
AstraZeneca has announced a planned $15b expansion in China to build out R&D, manufacturing, and cell therapy capabilities.
The company is forming a new alliance with CSPC Pharmaceuticals focused on next generation obesity and diabetes treatments.
The CSPC partnership includes access to advanced injection technologies and AI supported drug discovery.
AstraZeneca (LSE:AZN) is putting fresh attention on two areas investors are watching closely: China and metabolic disease. The shares recently...